The trial is taking place at:
A

AZ Sint-Lucas | Center for Clinical Studies

Veeva-enabled site

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis (Flex-Up)

AbbVie logo

AbbVie

Status and phase

Active, not recruiting
Phase 4

Conditions

Atopic Dermatitis

Treatments

Drug: Upadacitinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT05507580
M22-000
2022-000434-42 (EudraCT Number)

Details and patient eligibility

About

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide. The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Enrollment

461 patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and participant meets Hanifin and Rajka criteria.
  • Eczema Area and Severity Index (EASI) score >= 16, vIGA-AD score >= 3 and >= 10% Body Surface Area (BSA) of AD involvement at the Baseline Visit.
  • Baseline weekly average of daily Worst Pruritus NRS >= 4.
  • Candidate for systemic treatment defined as prior use of systemic treatment for AD, OR previous inadequate response to TCS, TCI or PDE-4 inhibitors, OR for whom topical treatments are otherwise medically inadvisable.

Exclusion criteria

Participants with current or past history of infection including:

  • Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;
  • One or more episodes of disseminated herpes simplex (including eczema herpeticum);
  • Human immunodeficiency virus (HIV) infection defined as confirmed positive anti-HIV antibody (HIV Ab) test;
  • Active tuberculosis (TB) or meet TB exclusionary parameters (protocol specified requirements for TB testing);
  • Japan only: Positive result of beta-D-glucan (screening for Pneumocystis jirovecii infection) or two consecutive indeterminate results of beta-D-glucan during the Screening Period;
  • Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit;
  • Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study;
  • COVID-19 infection: In participants who tested positive for COVID, at least 5 days must have passed since a COVID-19 positive test result for study entry of asymptomatic participants. Participants with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Participants may be rescreened if judged to be in good general health, as determined by the investigator based upon the medical history and physical examination.
  • Evidence of Hepatitis B virus (HBV) or Hepatitis C virus (HCV).

Any of the following medical diseases or disorders:

  • Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery;
  • History of an organ transplant which requires continued immunosuppression;
  • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class;
  • History of gastrointestinal perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for gastrointestinal perforation per investigator judgment;
  • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; participants with a history of gastric banding/segmentation are not excluded;
  • History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

461 participants in 6 patient groups

Double-Blind Treatment Period Dose A
Experimental group
Description:
Participants will be administered updadacitinib Dose A once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib
Double-Blind Treatment Period Dose B
Experimental group
Description:
Participants will be administered updadacitinib Dose B once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib
Single-Blinded Treatment Period Arm A
Experimental group
Description:
Participants will be administered updadacitinib once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib
Single-Blinded Treatment Period Arm B
Experimental group
Description:
Participants will be administered updadacitinib once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib
Single-Blinded Treatment Period Arm C
Experimental group
Description:
Participants will be administered updadacitinib once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib
Single-Blinded Treatment Period Arm D
Experimental group
Description:
Participants will be administered updadacitinib once daily (QD) for 12 weeks.
Treatment:
Drug: Upadacitinib

Trial contacts and locations

107

Loading...

Central trial contact

ABBVIE CALL CENTER

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems